CONFERENCE ON THE COMPLICATIONS OF TREATMENT

促进治疗并发症研究的规划 儿童和青少年的癌症，我们建议举行为期三天的 关于这个话题的会议。第二国际的目标 治疗儿童和青少年长期并发症会议 青少年癌症将： A）教育参与者关于疾病的病理学和病理生理学， 辐射相关和蒽环类药物相关的心脏损害; B）教育参与者了解当前的评估方法， 心脏功能，包括心电图和超声心动图; C）教育参与者有关心功能不全的频率 在儿童期和青春期接受治疗的患者人群中， 潜在心脏毒性治疗; D）教育参与者了解其他当前的长期研究 儿童癌症幸存者;以及 E）通过以下方式促进与会者之间的互动 圆桌讨论会， 第一次会议。 会议将包括国家和 国际公认的辐射领域专家， 蒽环类药物相关的心脏病理学， 蒽环类药物相关性心肌病，心功能评价 长期存活者心脏功能的临床研究 儿童和青少年癌症。所有被推荐的演讲者都有 同意参加会议。 会议将提出有关评价的建议， 暴露于心脏毒性药物的患者的临床管理和随访 这些疗法将通过出版 诉讼

To facilitate planning for research into the complications of treatment of children and adolescents for cancer, we propose to hold a three-day conference on this topic. The goals of The Second International Conference on Long-Term Complications of Treatment of Children and Adolescents for Cancer will be to: A) Educate participants regarding the pathology and pathophysiology of radiation related and anthracycline related cardiac damage; B) Educate participants regarding current methods for evaluation of cardiac function, including electrocardiography and echocardiography; C) Educate participants regarding the frequency of cardiac dysfunction in populations of patients treated during childhood and adolescence with potentially cardiotoxic therapy; D) Educate participants regarding other current research on long-term survivors of childhood cancer; and E) Facilitate interaction among conference participants through roundtable discussions of topics suggested by the participants in the first conference. The conference will include presentations by nationally and internationally recognized experts in the areas of radiation and anthracycline related cardiac pathology, the pathophysiology of anthracycline related cardiomyopathy, the evaluation of cardiac function and clinical investigation of cardiac function in long-term survivors of pediatric and adolescent cancer. All of the suggested speakers have agreed to participate in the conference. The conference will lead to recommendations regarding evaluation, clinical management and follow-up of patients exposed to cardiotoxic therapies which will be disseminated through the publication of the Proceedings.